Background
Survivors of myocardial infarction (MI) or stroke are at high risk for subsequent cardiovascular events. There is limited assessment of the effectiveness of risk factor modification through current secondary preventive strategies in the US population. We determined the adequacy of risk factor modification in 1252 survivors of MI, stroke, or both in a nationally representative sample of US adults and identified factors related to inadequate control of risk factors.
Methods
The adequacy of control for hypertension, diabetes mellitus, cigarette smoking, alcohol use, and hypercholesterolemia was assessed by personal interview, blood pressure measurements, and serum glycosylated hemoglobin and cholesterol levels in 17 752 US adults who participated in the Third National Health and Nutrition Examination Survey between 1988 and 1994. We also evaluated the role of potentially related factors, including age, sex, race/ethnicity, educational attainment, socioeconomic status, and medical insurance status using multivariate logistic regression analysis.
Results
Of 738 known hypertensive persons, hypertension was uncontrolled in 388 (53%). Previously undiagnosed hypertension was detected in 138 others (11%). Of 289 diabetic persons, serum glucose control was inadequate in 141. Of 1252 survivors, 225 (18%) were currently smoking, and heavy alcohol use was observed in 56 persons. Hypercholesterolemia was poorly controlled in 185 (46%) of 405 persons with known hypercholesterolemia. Undetected hypercholesterolemia was observed in 160 persons (13%). In the multivariate analysis, high-risk profiles were more likely to be observed in persons aged 46 to 65 years, women, and African Americans.
Conclusions
High prevalence of inadequate secondary prevention was found in a subset of the US population at highest risk for stroke and MI. Considerable efforts are required to effectively implement risk factor modification strategies after MI or stroke, particularly in middle-aged persons, African Americans, and women.
CARDIOVASCULAR diseases (CVDs), including myocardial infarction (MI) and stroke, are a major cause of death and disability in the United States.1 A history of CVD increases the relative risk of subsequent premature cardiovascular morbidity and mortality by 5 to 7 times.2,3 The survival rate among more than 1 million cases of MI that occur annually is approximately 70% to 80%.4,5 Among survivors of a first MI, the rate of subsequent MI is increased 3 to 6 times, and the risk of any CVD event may be as high as 80%.6 Of approximately 500 000 new and recurrent strokes that occur each year in the United States, 80% of the patients survive the event.7 The risk of subsequent ischemic stroke is as high as 30%, with a 2-fold increase in subsequent cardiovascular events.8-10 Because persons with a previous history of cardiovascular events are at high risk for future MI and stroke, aggressive intervention that includes risk factor modification is warranted in this population. Despite advances in medical and surgical management of CVD, long-term survival depends on modification of underlying disease processes. Considerable evidence exists that a secondary prevention program to reduce CVD risk factors can favorably impact CVD morbidity and mortality.4 Survivors of these events are ideal candidates for secondary prevention efforts because even modest treatment effects could benefit this large at-risk population. Most survivors receive medical evaluation regularly, and risk factor modification can be undertaken in a cost-effective manner. To our knowledge, limited information exists regarding formal assessment of the magnitude of risk factor modification with current secondary preventive strategies outside clinical trials. The present study was undertaken to determine the effectiveness of secondary preventive measures in survivors of MI and stroke using data from the Third National Health and Nutrition Examination Survey (NHANES III), a nationally representative sample of US adults, and to identify factors related to inadequate control of risk factors.
The NHANES III was conducted by the Centers for Disease Control and Prevention between 1988 and 1994 to estimate the prevalence of common chronic conditions and associated risk factors in a nationally representative sample of the civilian, noninstitutionalized US population.11 The survey included a household interview; a medical examination in a mobile examination center, or at home for those unable to travel; and phlebotomy to measure hematologic factors, including glucose control, cholesterol level, high-density lipoprotein cholesterol level, triglycerides, and apolipoproteins A-I and B.12,13 Participants were considered to have experienced a stroke if they reported a physician diagnosis of stroke and an MI if they reported a physician diagnosis of heart attack.
We evaluated the frequency and characteristics of the defined risk factors of hypertension, diabetes mellitus, hypercholesterolemia, alcohol use, and cigarette smoking in stroke and MI survivors. The prevalence of uncontrolled hypertension (defined as average blood pressure >140/90 mm Hg from 3 consecutive readings) in persons with diagnosed hypertension was estimated. The prevalence of undiagnosed hypertension (defined as average blood pressure >140/90 mm Hg from 3 consecutive readings) in persons with no previous diagnosis of hypertension was also determined. Diabetes mellitus was defined as either a physician diagnosis of diabetes mellitus or sugar diabetes or current use of insulin or oral hypoglycemic agents. Control of diabetes was determined according to serum glycosylated hemoglobin levels. Levels greater than 7.0 were considered indicative of poor control. Current smoking status was categorized as active, previous, or never. Alcohol use was categorized as heavy if the persons reported having more than 9 drinks per day at least 7 days per year or more than 5 drinks per day at least 14 days per year. Uncontrolled hypercholesterolemia, defined as a serum cholesterol level greater than 6.21 mmol/L (>240 mg/dL), was estimated separately for participants with diagnosed hypercholesterolemia. Previously undiagnosed hypercholesterolemia was defined as a serum cholesterol level greater than 6.21 mmol/L (>240 mg/dL). The diagnosis of hypercholesterolemia was based on the guidelines of the National Cholesterol Education Program I (NCEP I), which were available in 1988 at initiation of the study.14 The updated guidelines (NCEP II) were not used because they were not available until the end of the survey.15 Physical activity was graded using the response to the question, "Compared with most men/women of your age, would you say that you are more active, less active, or about the same?" Overweight status was defined by a body mass index (calculated as weight in kilograms divided by the square of height in meters) of 27.3 or greater in women and 27.8 or greater in men.16 As part of the interview, participants were asked whether their physicians prescribed any medication for treatment of hypertension or hypercholesterolemia. Participants were also questioned regarding whether they took the medication as prescribed by their physician to determine the status of compliance with treatment. As a separate analysis, individual components of the dietary intake of survivors were compared with the NCEP I guidelines to determine the adequacy of dietary habits.14
Another analysis was performed to identify the strata of high-risk persons who might benefit most from secondary prevention. High-risk profile was defined by the presence of 2 or more of the following characteristics: poorly controlled or undiagnosed hypertension, poorly controlled diabetes mellitus, active smoking, heavy alcohol use, or uncontrolled or undiagnosed hypercholesterolemia. The association of a high-risk profile with age, sex, race/ethnicity, medical insurance status, and educational attainment was evaluated using logistic regression analysis. Age was categorized in 3 groups before entry into the model: younger than 46 years, 46 to 65 years, and older than 65 years. Race/ethnicity was grouped as white, African American, or other. Other variables were dichotomized based on presence or absence. To estimate the extent of medical follow-up and evaluation in participants with and without a high-risk profile, we compared the number of visits to the physician's office within the past year for each group. We also compared the frequency with which participants with and without high-risk profiles had seen a physician or health professional within the past 6 months.
Economic status was estimated for 948 persons as poverty index. Poverty index was computed as a ratio of 2 components. The numerator was the midpoint of the observed family income category. The denominator was the poverty threshold, the age of the family reference person, and the calendar year in which the family was interviewed. The poverty index allowed income data to be analyzed in a comparable manner across the 6 years of the survey and with previous surveys. A higher poverty index suggests higher income and economic status. A separate logistic regression analysis was performed in participants in whom poverty index was available to analyze the effect of economic status on the presence of multiple uncontrolled risk factors. Poverty index was categorized based on quartiles.
Of 17 752 adults older than 18 years who underwent complete interview and examination in the NHANES III, 1252 survivors of MI, stroke, or both were identified. A total of 828 participants reported a physician diagnosis of MI, 560 reported a previous diagnosis of stroke, and 136 reported a history of both. The mean ± SD interval between the event and the present NHANES III evaluation was 10.6 ± 9.4 years for MI and 8.0 ± 9.6 years for stroke.
Hypertension had been previously diagnosed in 738 persons (59%). According to our criteria, hypertension was controlled in 280 participants (38%) and uncontrolled in 388 (53%). Blood pressure readings were not available for 70 persons (9%). The distribution of systolic and diastolic blood pressures among survivors of MI and stroke is shown in Figure 1 and Figure 2, respectively. Most participants with elevated systolic blood pressure had readings between 140 and 180 mm Hg. Critical analysis of the data for 388 persons with uncontrolled hypertension revealed that noncompliance (n = 49) and lack of prescribed medication or treatment advice (n = 7) contributed minimally to poor control. Of the 388 participants, 350 reported evaluation by a medical physician or other health professional within the past 6 months. Previously undiagnosed hypertension was detected in 138 survivors, of whom 117 reported evaluation by a physician or other health professional within the past 6 months. A total of 289 participants were known diabetics; 110 required insulin treatment, 128 used oral hypoglycemic agents, 16 used both, and 67 were not using any medication. Serum glucose control, as reflected by glycosylated hemoglobin levels, was adequate in 136 persons with diabetes (47%) and inadequate in 141 (49%). Levels were not available for 12 persons (4%). Of 1252 survivors, 225 (18%) were currently smoking and 530 (42%) reported a past history of smoking. Heavy alcohol use was observed in 56 persons (4%). Hypercholesterolemia previously diagnosed in 405 survivors (32%) was considered to be adequately controlled in 199 (49%) and poorly controlled in 185 (46%) based on our criteria. Cholesterol levels were not available for 21 persons. Distribution of serum total cholesterol levels in survivors of MI and stroke is shown in Figure 3. Most participants with elevated concentrations of cholesterol had levels between 6.21 and 7.24 mmol/L (240 and 280 mg/dL). Of 185 persons with poorly controlled hypercholesterolemia, noncompliance to medication was reported by 23 and no prescribed treatment was reported by 12; 176 had seen a medical professional in the past 6 months. Previously undiagnosed hypercholesterolemia was detected in 160 persons, of which 133 reported a recent (<6 months) evaluation by a health professional. Low-density lipoprotein cholesterol level was evaluated in 417 participants (Figure 4); 236 (57%) had levels greater than 3.36 mmol/L (>130 mg/dL). Physical activity compared with their peers was graded as more active by 28% of respondents, about the same by 38%, and as less active by 34%. A total of 543 participants (43%) were considered overweight.
Table 1 compares inadequately controlled risk factors in persons with vs without previous stroke or MI in the NHANES III. The group with previous MI or stroke was older and had a higher proportion of men and whites. The frequency of participants with inadequately controlled hypertension, hypercholesterolemia, and diabetes mellitus was higher in persons with previous stroke or MI. The proportions of current smokers and heavy alcohol users were lower in persons with previous stroke or MI. The comparison does not adjust for demographic differences between the 2 groups.
Analysis of dietary consumption revealed that the following components were not in accordance with NCEP I guidelines: total fat greater than 30% of total calories (n = 646), saturated fatty acid greater than 10% of total calories (n = 580), polyunsaturated fatty acid greater than 10% of total calories (n = 181), monounsaturated fatty acid greater than 15% of total calories (n = 278), cholesterol level greater than 7.76 mmol/L (>300 mg/dL) (n = 328), and carbohydrates greater than 60% of total calories (n = 228).
Of 1060 survivors with complete data for multivariate analysis, 366 (35%) had a high-risk profile, defined as the presence of 2 or more poorly controlled risk factors. In the multivariate analysis, those aged 46 to 65 years (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.3-4.8), women (OR, 1.6; 95% CI, 1.3-2.1), and African Americans (OR, 1.4; 95% CI, 1.0-1.9) were at significantly higher risk for having a high-risk profile (Table 2). The probability of having a high-risk profile was not affected by educational attainment or medical insurance status. In a separate analysis, poverty index was not associated with a high-risk profile. The mean ± SD number of evaluations by health professionals within the past year was similar in the high-risk group (6.9 ± 7.5) and the group with 1 or no uncontrolled risk factors (6.9 ± 8.6). Among the 366 high-risk persons, 326 (89%) reported a consultation with a medical professional within the past 6 months.
Salient findings of the study
Efforts aimed at secondary prevention in survivors of MI, stroke, or both are inadequate. The NHANES III represents one of the largest recent national population-based assessments of CVD risk factors in the United States.11 Therefore, these data afford a unique opportunity to evaluate the status of various socioeconomic, clinical, and hematologic factors in a representative population. Our results call for major efforts directed toward secondary prevention in a subset of the population at highest risk for CVD events. The magnitude of inadequate risk factor control was high, with almost half of persons with hypertension, diabetes mellitus, and hypercholesterolemia having inadequate risk factor control. One fifth of MI and stroke survivors were currently smoking. This ineffectiveness was in part the result of patient attitudes toward risk factor modification, as evident from medication noncompliance and active cigarette smoking. However, a large proportion of undetected hypertension and hypercholesterolemia also suggests the inadequacy of regular medical evaluation regarding secondary prevention in this population. Almost 90% of the high-risk group reported that they had seen a physician or other health professional in the past 6 months. Participants reported an average of 7 consultations with physicians or other health professionals within the past year.
Comparison with other studies
Table 3 compares our results with those of similar studies conducted within and outside the United States.17-20 The proportion of uncontrolled hypertension and current smoking was similar among studies. The hyperlipidemia profile varies in studies depending on the age and sex distributions. The higher proportion of inadequately controlled hyperlipidemia in the Heart and Estrogen/Progestin Replacement Study and the Health Education and Research Trial might also be attributed to use of low-density lipoprotein cholesterol level to define hyperlipidemia. Some data for secondary prevention are also available from recent trials evaluating the effect of cholesterol lowering in patients with coronary heart disease and high or average cholesterol levels in the Scandinavian Simvastatin Survival Study,21 the Cholesterol and Recurrent Events trial,22 and the Long-term Intervention With Pravastatin in Ischaemic Disease Study.23 However, study inclusion criteria limit the extrapolation of these data to reflect the secondary prevention status in the general population.
Risk reduction with secondary prevention
Uncontrolled hypertension (systemic blood pressure >140/90 mm Hg) was observed in 53% of participants with previously diagnosed hypertension. An additional 138 survivors (11%) had hypertension that was previously undetected. Noncompliance and lack of prescribed medication or treatment advice contributed minimally to poor control. Participants in the Hypertension Detection and Follow-up Program who had a previous history of MI had a 20% reduction in the total mortality rate.24 Uncontrolled hypertension in survivors of stroke is associated with poor prognosis.25,26 Direct evidence suggesting a link between stroke recurrence reduction and blood pressure reduction is lacking. A study27 comparing aggressive antihypertensive treatment with standard care demonstrated a 20% stroke reduction in patients with previous evidence of end-organ damage, including stroke. Poor control of diabetes mellitus was observed in 49% of participants with diabetes. Stroke survivors with diabetes have a 2-fold higher risk of subsequent stroke and MI than do those without diabetes.28 Whether aggressive glucose control reduces the risk of CVD events is debated.29 Reduction of CVD risk might depend more on control of other coexisting risk factors, such as obesity, hypertension, and lipid abnormalities.29 However, poor glycemic control can exacerbate or cause dyslipidemia.4 Smoking remains the most modifiable risk factor for MI and stroke survivors.30,31 Cessation of smoking after MI results in a 50% reduction in subsequent CVD events (compared with those who continue to smoke) independent of other factors.32 A 70% reduction in MI and death was reported in men and women older than 55 years with angiographically demonstrated coronary artery disease who quit smoking.33
A high frequency of uncontrolled hypercholesterolemia was also observed in survivors. Cholesterol lowering for secondary prevention after MI has been shown to reduce the risk of subsequent MI.21-23 In the Coronary Drug Project, the mortality rate over a 15-year period was 11% lower in the niacin therapy group than in the placebo group.34 The maximum benefit was observed after 12 years of follow-up. In the West of Scotland Coronary Prevention Study, participants with or without previous coronary heart disease were randomized to receive pravastatin or placebo.35 The study concluded that the absolute benefit of pravastatin treatment for hypercholesterolemia was most prominent when used for secondary prevention of MI. The role of hypercholesterolemia is less well defined for secondary prevention of stroke. An overview analysis of 16 trials evaluating antilipidemic medications demonstrated a significant reduction in cardiovascular events and death and stroke.36 The beneficial effect was seen in patients with or without previous coronary artery disease.
Impact of recent clinical trials and guidelines
In recognition of the importance of this issue, the NCEP has carried out a variety of educational activities to develop and implement guidelines for treatment of elevated cholesterol levels.37 The first guidelines were available in 1988 at initiation of the study.14 The guidelines were updated in 1993 before completion of the present survey.15 Recent studies38,39 have also documented the benefits of antihypertensive treatment in patients with isolated systolic hypertension and diabetes mellitus. The physicians' practices might have been affected by these studies since data collection in the NHANES III. Therefore, the effect of the updated guidelines and recent clinical trials might be undermined in the present study. More recent studies still continue to demonstrate the inadequacy of secondary prevention (Table 3). Frolkis et al40 reported that 36% of hospitalized patients and 46% of patients who should be treated for hyperlipidemia at discharge from coronary care units according to NCEP II guidelines were not treated. The study concluded that physicians are poorly compliant with NCEP guidelines.
Inadequate dietary intake
In our study, a large proportion of participants had dietary habits that were not in accordance with NCEP I guidelines. This observation might have important implications as accumulating evidence suggests the role of diet in modification of hypertension and hypercholesterolemia.41,42 In the Lyon Diet Heart Study, the risk of cardiac death or nonfatal MI was lower in the Mediterranean dietary group than in the prudent Western-type dietary group.43 The protective effect was maintained for 4 years after the first MI.
Factors related to inadequate secondary prevention
Our analysis suggests that attitudes toward risk factor modification, as seen in participants who were noncompliant with medications or continued to smoke, were a determinant of inadequate secondary prevention. Patient education and awareness efforts might favorably impact this issue. However, the analysis also suggests that a substantial proportion of survivors had hypertension or hypercholesterolemia that was not previously diagnosed. This observation highlights the importance of regular medical evaluation and follow-up in survivors of MI or stroke. Three population subsets were more likely to have an inadequately controlled CVD risk factor profile: middle-aged persons (46-65 years), African Americans, and women. The present study was not designed to determine the underlying reasons behind the association of age or sex with poor control of risk factors. However, the analysis identifies persons who might benefit most from risk factor modification efforts. Educational attainment and access to medical care as reflected by medical insurance status were not related to risk factor status. Furthermore, almost 90% of persons with poorly controlled risk factors had seen a medical professional in the past 6 months. Persons with high-risk profiles reported an average of 7 visits to the physician's office within the past year. These observations emphasize the lack of implementation of secondary preventive strategies despite frequent medical evaluations.
Economic impact of secondary prevention
The economic burden of CVD in the United States is estimated to be $286.5 billion dollars annually.44 Lightwood and Glantz45 estimated that a 1% reduction per year in the prevalence of smoking could result in savings of $3.2 billion over 7 years. Grover et al46 estimated that treatment of hypercholesterolemia in persons with CVD could result in an estimated 4.65 years of life saved. Similarly, treatment of hypertension could increase life expectancy by approximately 1.26 years. In their analysis, the forecasted benefits were prominent in primary prevention only when persons had multiple risk factors. However, the forecasted benefit was observed in secondary prevention in persons with single or multiple risk factors. We hope that our analysis encourages policymakers to increase funding to support secondary preventive efforts. At the individual physician level, a more thorough effort toward ensuring patient understanding of the importance of risk factor modification and regular medical evaluation might ensure compliance and early detection of new-onset hypertension or hypercholesterolemia.
Issue related to data interpretation
There are certain potential limitations to this study. The definitions of MI and stroke used to identify participants with previous CVDs were based on self-reported physician diagnoses. Previous studies have suggested that self-reported MI in the NHANES surveys is reasonably accurate to justify its use in assessment of risk factor and prevalence studies. A study47 was conducted in the early years of the National Health Survey to measure the accuracy and completeness of health interviews that concluded that the frequency of underreporting or overreporting was low for heart diseases. Bergmann et al48 compared interview reports with hospitalization records for 10 523 participants from NHANES I. The interview consisted of the same question for MI as used in NHANES III with a similar study population. A true-positive rate of 83% (95% CI, 78%-87%) was observed for the 294 self-reported MIs. O'Mahony et al49 validated the accuracy of assessing lifetime history of stroke in a random sample of 2000 persons aged 45 years and older in a mailed questionnaire. Participants were asked whether they ever had a stroke. Response accuracy was confirmed by review of medical records. The question had a sensitivity of 95% and a specificity of 96%. Similarly, high sensitivity (74%-100%) and specificity (94%-99%) have been reported for estimation of prevalent MI by means of mailed questionnaires.50,51 The status of certain risk factors such as smoking and compliance to medication was based on self-report without independent confirmation, which might undermine the prevalence of current smoking and compliance to medication. Similarly, the definition of undetected hypertension and hypercholesterolemia based on self-report is affected by participants' awareness of such a diagnosis in addition to detection by a physician. Because the study was not longitudinal, there is a possibility that control of risk factors might have improved after the event compared with risk factor status before the event but might not have achieved the optimal level defined in our study. The number of participants available for analysis was relatively small (n = 1252) but was comparable to that in other studies (Table 3).
Our analysis shows a high prevalence of inadequate secondary prevention in a subset of the US population at highest risk for stroke and MI. Strong motivation and regular access to medical care make MI and stroke survivors ideal candidates for education programs and medical treatment. Secondary prevention strategies are cost-effective because high-risk individuals are already identified by the medical system, and small efforts can make a large impact on outcome because of the large number of expected events. Most efforts need to be focused on African Americans, women, and persons aged 46 to 65 years. Unless risk factor modification efforts in survivors of MI and stroke are more effective, the high incidence of CVD and related mortality will continue.
Accepted for publication November 7, 2000.
Presented in part (abstract) at the 26th International Stroke Conference, American Stroke Association, Fort Lauderdale, Fla, February 14, 2001 (Stroke. 2001;32:320[abstract]).
Corresponding author and reprints: Adnan I. Qureshi, MD, Department of Neurosurgery, Millard Fillmore Hospital, 3 Gates Cir, Buffalo, NY 14209-1194 (e-mail: aiqureshi@hotmail.com).
1.American Heart Association, 1993 Heart and Stroke Facts. Dallas, Tex American Heart Association1992;
2.Johansson
SBergstrand
RUlvenstam
G
et al. Sex differences in preinfarction characteristics and long-term survival among patients with myocardial infarction.
Am J Epidemiol. 1984;119610- 623
Google Scholar 3.Kannel
WBSorlie
PMcNamara
PM Prognosis after initial myocardial infarction: the Framingham Study.
Am J Cardiol. 1979;4453- 59
Google ScholarCrossref 4.Robinson
JGLeon
AS The prevention of cardiovascular disease: emphasis on secondary prevention.
Med Clin North Am. 1994;7869- 98
Google Scholar 5.Garraway
WMElveback
LRConnolly
DCWhisnant
JP The dichotomy of myocardial and cerebral infarction.
Lancet. 1983;21332- 1335
Google ScholarCrossref 6.Schlant
RCForman
SStamler
JCanner
PL The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men: the 5-year findings of the Coronary Drug Project.
Circulation. 1982;66401- 414
Google ScholarCrossref 7.Shahar
EMcGovern
PGSprafka
JM
et al. Improved survival of stroke patients during the 1980s: the Minnesota Stroke Survey.
Stroke. 1995;261- 6
Google ScholarCrossref 8.Kernan
WNHorwitz
RIBrass
LMViscoli
CMTaylor
KJ A prognostic system for transient ischemia or minor stroke.
Ann Intern Med. 1991;114552- 557
Google ScholarCrossref 9.The Canadian Cooperative Study Group, A randomized trial of aspirin and sulfinpyrazone in threatened stroke.
N Engl J Med. 1978;29953- 59
Google ScholarCrossref 10.Dennis
MBamford
JSandercock
PWarlow
C Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project.
Stroke. 1990;21848- 853
Google ScholarCrossref 11.Not Available, Plan and operation of the Third National Health and Nutrition Examination Survey, 1988-94, series 1: programs and collection procedures.
Vital Health Stat 1. July1994;1- 407
Google Scholar 12.Sempos
CTCleeman
JICarroll
MD
et al. Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel.
JAMA. 1993;2693009- 3014
Google ScholarCrossref 13.Johnson
CLRifkind
BMSempos
CT
et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys.
JAMA. 1993;2693002- 3008
Google ScholarCrossref 14.The Expert Panel, Report of the National Cholesterol Education Program on Detection, Evaluation, and Treatment of High Cholesterol in Adults.
Arch Intern Med. 1988;14836- 69
Google ScholarCrossref 15.Not Available, Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.
JAMA. 1993;2693015- 3023
Google ScholarCrossref 16.Qureshi
AIGiles
WHCroft
JBBliwise
DL Habitual sleep patterns and risk for stroke and coronary heart disease: a 10-year follow-up from NHANES I.
Neurology. 1997;48904- 911
Google ScholarCrossref 17.EUROASPIRE (European Action on Secondary Prevention through Intervention to Reduce Events) Study Group, EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results.
Eur Heart J. 1997;181569- 1582
Google ScholarCrossref 18.Schrott
HGBittner
VVittinghoff
EHerrington
DMHulley
SHERS Research Group, Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease: the Heart and Estrogen/Progestin Replacement Study (HERS).
JAMA. 1997;2771281- 1286
Google ScholarCrossref 19.McBride
PSchrott
HGPlane
MBUnderbakke
GBrown
RL Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease.
Arch Intern Med. 1998;1581238- 1244
Google ScholarCrossref 20.Bowker
TJClayton
TCIngham
J
et al. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events).
Heart. 1996;75334- 342
Google ScholarCrossref 21.The Scandinavian Simvastatin Survival Study Group, Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction.
Am J Cardiol. 1993;71393- 400
Google ScholarCrossref 22.Plehn
JFDavis
BRSacks
FM
et al. CARE Investigators, Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study.
Circulation. 1999;99216- 223
Google ScholarCrossref 23.The Long-term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med. 1998;3391349- 1357
Google ScholarCrossref 24.Langford
HGStamler
JWassertheil-Smoller
SPrineas
RJ All-cause mortality in the Hypertension Detection and Follow-up Program: findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality.
Prog Cardiovasc Dis. 1986;2929- 54
Google ScholarCrossref 26.Rabkin
SWMathewson
FATate
RB The relation of blood pressure to stroke prognosis.
Ann Intern Med. 1978;8915- 20
Google ScholarCrossref 27.Hypertension Detection and Follow-up Program Cooperative Group, Five-year findings of the Hypertension Detection and Follow-up Program, III: reduction in stroke incidence among persons with high blood pressure.
JAMA. 1982;247633- 638
Google ScholarCrossref 28.Olsson
TViitanen
MAsplund
KEriksson
SHagg
E Prognosis after stroke in diabetic patients: a controlled prospective study.
Diabetologia. 1990;33244- 249
Google ScholarCrossref 29.Kannel
WB Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.
Am Heart J. 1985;1101100- 1107
Google ScholarCrossref 30.Taylor
CBHouston-Miller
NHaskell
WLDebusk
RF Smoking cessation after acute myocardial infarction: the effects of exercise training.
Addict Behav. 1988;13331- 335
Google ScholarCrossref 31.Genest
JJMcNamara
JRSalem
DNSchaefer
EJ Prevalence of risk factors in men with premature coronary artery disease.
Am J Cardiol. 1991;671185- 1189
Google ScholarCrossref 32.Aberg
ABergstrand
RJohansson
S
et al. Cessation of smoking after myocardial infarction: effects on mortality after 10 years.
Br Heart J. 1983;49416- 422
Google ScholarCrossref 33.Hermanson
BOmenn
GSKronmal
RAGersh
BJ Beneficial six-year outcome of smoking cessation in older men and women with coronary artery disease: results from the CASS registry.
N Engl J Med. 1988;3191365- 1369
Google ScholarCrossref 34.Canner
PLBerge
KGWenger
NK
et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
J Am Coll Cardiol. 1986;81245- 1255
Google ScholarCrossref 35.West of Scotland Coronary Prevention Study Group, West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.
Lancet. 1996;3481339- 1342
Google ScholarCrossref 36.Hebert
PRGaziano
JMChan
KSHennekens
CH Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials.
JAMA. 1997;278313- 321
Google ScholarCrossref 37.Cleeman
JILenfant
C The National Cholesterol Education Program: progress and prospects.
JAMA. 1998;2802099- 2104
Google ScholarCrossref 38.SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).
JAMA. 1991;2653255- 3264
Google ScholarCrossref 39.White
WBPrisant
LMWright Jr
JT Management of patients with hypertension and diabetes mellitus: advances in the evidence for intensive treatment.
Am J Med. 2000;108238- 245
Google ScholarCrossref 40.Frolkis
JPZyzanski
SJSchwartz
JMSuhan
PS Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines.
Circulation. 1998;98851- 855
Google ScholarCrossref 41.Gordon
NFScott
CBLevine
BD Comparison of single versus multiple lifestyle interventions: are the antihypertensive effects of exercise training and diet-induced weight loss additive?
Am J Cardiol. 1997;79763- 767
Google ScholarCrossref 42.Kinosian
BPEisenberg
JM Cutting into cholesterol: cost-effective alternatives for treating hypercholesterolemia.
JAMA. 1988;2592249- 2254
Google ScholarCrossref 43.de Lorgeril
MSalen
PMartin
JL
et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study.
Circulation. 1999;99779- 785
Google ScholarCrossref 44.American Heart Association, Economic Costs of Cardiovascular Diseases. Dallas, Tex American Heart Association Inc1999;
45.Lightwood
JMGlantz
SA Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke.
Circulation. 1997;961089- 1096
Google ScholarCrossref 46.Grover
SAPaquet
SLevinton
CCoupal
LZowall
H Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention.
Arch Intern Med. 1998;158655- 662
Google ScholarCrossref 47.Madow
WG Net differences in interview data on chronic conditions and information derived from medical records.
Vital Health Stat 1. 1973;21- 58
Google Scholar 48.Bergmann
MMByers
TFreedman
DS
et al. Validity of self-reported diagnoses leading to hospitalization: a comparison of self-reports with hospital records in a prospective study of American adults.
Am J Epidemiol. 1998;147969- 977
Google ScholarCrossref 49.O'Mahony
PGDobson
RRodgers
H
et al. Validation of a population screening questionnaire to assess prevalence of stroke.
Stroke. 1995;261334- 1337
Google ScholarCrossref 50.Olsson
LSvardsudd
KNilsson
G
et al. Validity of a postal questionnaire with regard to the prevalence of myocardial infarction in a general population sample.
Eur Heart J. 1989;101011- 1016
Google Scholar 51.Hagman
MJonsson
DWilhelmsen
L Prevalence of angina pectoris and myocardial infarction in a general population sample of Swedish men.
Acta Med Scand. 1977;201571- 577
Google ScholarCrossref